ArticleIJID regions2026
Blood kynurenine pathway metabolites show limited diagnostic utility for tuberculosis among adults living with human immunodeficiency virus and children in Uganda.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Traditional sputum-based diagnostics often demonstrate suboptimal diagnostic performance in people living with human immunodeficiency virus and children presenting with paucibacillary tuberculosis (TB). This study evaluated the diagnostic accuracy of circulating kynurenine-pathway metabolites against an authentic symptomatic control cohort in Uganda. Methods: Tryptophan, kynurenine, and the kynurenine-to-tryptophan ratio were quantified via ultra-performance liquid chromatography-tandem mass spectrometry in 70 adult people living with human immunodeficiency virus and 23 children presenting with presumptive TB. Results: Median biomarker concentrations demonstrated no statistically significant differences between participants with laboratory-confirmed TB and symptomatic controls. The kynurenine-to-tryptophan ratio yielded an area under the curve of 0.51 (95% confidence interval: 0.34-0.69) in adults and 0.62 (95% confidence interval: 0.36-0.87) in children, indicating limited diagnostic discrimination with substantial uncertainty, particularly in the small pediatric cohort. At the evaluated cutoff points, none of the biomarkers met the minimum sensitivity and specificity requirements defined by the World Health Organization target product profiles for diagnostic and screening tests. Conclusion: Blood kynurenine pathway metabolites demonstrated limited clinical utility as standalone diagnostic biomarkers for active TB in these vulnerable populations. In addition, larger diagnostic performance studies are needed to address the uncertainty associated with the small sample size and to further validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.